| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| L Tenenbaum, A Chtarto, E Lehtonen, D Blum, V Baekelandt, T Velu, J Brotchi, M Levivie. Neuroprotective gene therapy for Parkinson's disease. Current gene therapy. vol 2. issue 4. 2003-05-14. PMID:12477256. |
parkinson's disease (pd) is a neurodegenerative disease characterised by a progressive loss of the dopaminergic neurones in the substantia nigra pars compacta. |
2003-05-14 |
2023-08-12 |
mouse |
| David G Le Couteur, Michael Muller, Maria C Yang, George D Mellick, Allan J McLea. Age-environment and gene-environment interactions in the pathogenesis of Parkinson's disease. Reviews on environmental health. vol 17. issue 1. 2002-12-24. PMID:12088093. |
parkinson's disease (pd) is a common neurodegenerative disease characterized by dopaminergic cell death and deposition of lewy bodies within the substantia nigra of the midbrain. |
2002-12-24 |
2023-08-12 |
Not clear |
| Srinivas Bharath, Michael Hsu, Deepinder Kaur, Subramanian Rajagopalan, Julie K Anderse. Glutathione, iron and Parkinson's disease. Biochemical pharmacology. vol 64. issue 5-6. 2002-10-17. PMID:12213603. |
parkinson's disease (pd) is a progressive neurodegenerative disease involving neurodegeneration of dopaminergic neurons of the substantia nigra (sn), a part of the midbrain. |
2002-10-17 |
2023-08-12 |
Not clear |
| Samina S Riaz, Eric Jauniaux, Gerald M Stern, Henry F Bradfor. The controlled conversion of human neural progenitor cells derived from foetal ventral mesencephalon into dopaminergic neurons in vitro. Brain research. Developmental brain research. vol 136. issue 1. 2002-08-27. PMID:12036514. |
therefore, the successful conversion of human foetal progenitor cells in vitro resulting in the desired dopaminergic neuronal phenotype, could provide a solution to the problem of limited availability of human foetuses for clinical surgical transplantation therapies, which are currently in progress for the treatment of neurodegenerative diseases such as parkinson's disease. |
2002-08-27 |
2023-08-12 |
human |
| Vladimir N Uversky, Anthony L Fin. Amino acid determinants of alpha-synuclein aggregation: putting together pieces of the puzzle. FEBS letters. vol 522. issue 1-3. 2002-08-14. PMID:12095610. |
parkinson's disease is the second most common neurodegenerative disease, and results from loss of dopaminergic neurons in the substantia nigra. |
2002-08-14 |
2023-08-12 |
mouse |
| Marlene Jimenez Del Rio, Carlos Velez-Pard. Monoamine neurotoxins-induced apoptosis in lymphocytes by a common oxidative stress mechanism: involvement of hydrogen peroxide (H(2)O(2)), caspase-3, and nuclear factor kappa-B (NF-kappaB), p53, c-Jun transcription factors. Biochemical pharmacology. vol 63. issue 4. 2002-05-17. PMID:11992635. |
the destruction of dopaminergic and serotonergic nerve cells by selective 6-hydroxydopamine (6-ohda), 5,6-dihydroxytryptamine (5,6-dht) and 5,7-dihydroxytryptamine (5,7-dht), respectively, is a commonly used tool to investigate the mapping of neuronal pathways, elucidation of function and to mimic human neurodegenerative disease such as parkinson's and alzheimer's diseases. |
2002-05-17 |
2023-08-12 |
human |
| Vladimir N Uversky, Elisa M Cooper, Kiowa S Bower, Jie Li, Anthony L Fin. Accelerated alpha-synuclein fibrillation in crowded milieu. FEBS letters. vol 515. issue 1-3. 2002-05-10. PMID:11943202. |
parkinson's disease is the second most common age-related neurodegenerative disease, resulting from loss of dopaminergic neurons in the substantia nigra. |
2002-05-10 |
2023-08-12 |
Not clear |
| S Porat, A Premkumar, R Simanto. Dopamine induces phenotypic differentiation or apoptosis in a dose-dependent fashion: involvement of the dopamine transporter and p53. Developmental neuroscience. vol 23. issue 6. 2002-04-12. PMID:11872944. |
these findings provide an insight into the role of dopamine, dopamine transporters and p53 in the differentiation and apoptosis of dopaminergic neurons, which will further our understanding of neuronal development and neurodegenerative diseases. |
2002-04-12 |
2023-08-12 |
human |
| Jeffrey A Cohlberg, Jie Li, Vladimir N Uversky, Anthony L Fin. Heparin and other glycosaminoglycans stimulate the formation of amyloid fibrils from alpha-synuclein in vitro. Biochemistry. vol 41. issue 5. 2002-02-19. PMID:11814343. |
parkinson's disease is the second most common neurodegenerative disease and results from loss of dopaminergic neurons in the substantia nigra. |
2002-02-19 |
2023-08-12 |
Not clear |
| A D Zurn, H R Widmer, P Aebische. Sustained delivery of GDNF: towards a treatment for Parkinson's disease. Brain research. Brain research reviews. vol 36. issue 2-3. 2002-02-08. PMID:11690619. |
parkinson's disease (pd) is a neurodegenerative disease characterized by the progressive loss of nigral dopaminergic neurons. |
2002-02-08 |
2023-08-12 |
monkey |
| B Liu, L Qin, S N Yang, B C Wilson, Y Liu, J S Hon. Femtomolar concentrations of dynorphins protect rat mesencephalic dopaminergic neurons against inflammatory damage. The Journal of pharmacology and experimental therapeutics. vol 298. issue 3. 2001-09-13. PMID:11504811. |
understanding the underlying mechanisms of action should further define the roles of dynorphins in the regulation of dopaminergic neurons and help devise novel strategies to combat neurodegenerative diseases. |
2001-09-13 |
2023-08-12 |
rat |
| N A Muma, J M Lee, L Gorman, B A Heidenreich, I Mitrovic, T C Napie. 6-hydroxydopamine-induced lesions of dopaminergic neurons alter the function of postsynaptic cholinergic neurons without changing cytoskeletal proteins. Experimental neurology. vol 168. issue 1. 2001-03-29. PMID:11170728. |
these results suggest that removal of dopaminergic inputs to the forebrain results in hyperactivity of the cholinergic systems but is not sufficient to induce postsynaptic perturbations in cytoskeletal proteins which occur in neurodegenerative diseases. |
2001-03-29 |
2023-08-12 |
rat |
| E C Hirsc. Glial cells and Parkinson's disease. Journal of neurology. vol 247 Suppl 2. 2000-09-14. PMID:10991667. |
parkinson's disease is a neurodegenerative disease characterised by a massive loss of dopaminergic neurons in the substantia nigra. |
2000-09-14 |
2023-08-12 |
Not clear |
| R H Baloh, M G Tansey, E M Johnson, J Milbrand. Functional mapping of receptor specificity domains of glial cell line-derived neurotrophic factor (GDNF) family ligands and production of GFRalpha1 RET-specific agonists. The Journal of biological chemistry. vol 275. issue 5. 2000-03-02. PMID:10652334. |
the glial cell line-derived neurotrophic factor (gdnf) family ligands (gfls) (gdnf, neurturin, artemin, and persephin) are critical regulators of neurodevelopment and support the survival of midbrain dopaminergic and spinal motor neurons in vitro and in animal disease models making them attractive therapeutic candidates for treatment of neurodegenerative diseases. |
2000-03-02 |
2023-08-12 |
Not clear |
| W Hauber, S Lut. Dopamine D1 or D2 receptor blockade in the globus pallidus produces akinesia in the rat. Behavioural brain research. vol 106. issue 1-2. 2000-01-11. PMID:10595430. |
the findings further imply that defective dopaminergic transmission in the gp might contribute to akinesia due to lesion- or drug-induced dopamine hypofunction in experimental animals and in neurodegenerative diseases, e.g. |
2000-01-11 |
2023-08-12 |
rat |
| Y He, T Lee, S K Leon. Time-course and localization of transferrin receptor expression in the substantia nigra of 6-hydroxydopamine-induced parkinsonian rats. Neuroscience. vol 91. issue 2. 1999-08-02. PMID:10366015. |
parkinson's disease is a neurodegenerative disease characterized by dopaminergic cell death in the substantia nigra. |
1999-08-02 |
2023-08-12 |
rat |
| W S Joo, B K Jin, C W Park, S H Maeng, Y S Ki. Melatonin increases striatal dopaminergic function in 6-OHDA-lesioned rats. Neuroreport. vol 9. issue 18. 1999-04-13. PMID:9926859. |
taken together with our previous reports showing behavioral and histochemical effects of melatonin on the nigrostriatal dopaminergic system, the present results strongly support the hypothesis that melatonin, as an antioxidant, may have beneficial effects on therapeutic approaches for the treatment of oxidative stress-induced neurodegenerative disease such as parkinson's disease (pd). |
1999-04-13 |
2023-08-12 |
rat |
| b' K S Raevski\\xc4\\xa. [Functional role and pharmacological regulation of the dopaminergic system of the brain]. Vestnik Rossiiskoi akademii meditsinskikh nauk. issue 8. 1998-12-01. PMID:9771125.' |
the dopaminergic systems of the brain are thought to play a major role in the regulation of motor, cognitive, neuroendocrine functions and in the pathogenesis of several pathological conditions, including neurodegenerative diseases, affective disorders, schizophrenia, drug addiction, etc. |
1998-12-01 |
2023-08-12 |
rat |
| A Ho, M Blu. Induction of interleukin-1 associated with compensatory dopaminergic sprouting in the denervated striatum of young mice: model of aging and neurodegenerative disease. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 18. issue 15. 1998-08-07. PMID:9671653. |
induction of interleukin-1 associated with compensatory dopaminergic sprouting in the denervated striatum of young mice: model of aging and neurodegenerative disease. |
1998-08-07 |
2023-08-12 |
mouse |
| P A Lapcha. A preclinical development strategy designed to optimize the use of glial cell line-derived neurotrophic factor in the treatment of Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society. vol 13 Suppl 1. 1998-08-06. PMID:9613719. |
the pharmacologic profile of gdnf in two well-characterized animal models of parkinson's disease suggests that the molecule may be useful in the treatment of neurodegenerative diseases involving dopaminergic dysfunction such as parkinson's disease. |
1998-08-06 |
2023-08-12 |
Not clear |